Valuation: TScan Therapeutics, Inc.

Market Cap 5.1Cr 4.42Cr 4.14Cr 3.79Cr 7.15Cr 485.57Cr 7.25Cr 48Cr 19Cr 242.61Cr 19Cr 19Cr 807.49Cr P/E 2026 *
-0.89x
P/E 2027 * -0.85x
Enterprise Value -4.79Cr -4.16Cr -3.89Cr -3.56Cr -6.72Cr -456.23Cr -6.81Cr -46Cr -18Cr -227.95Cr -18Cr -18Cr -758.7Cr EV / Sales 2026 *
-6.34x
EV / Sales 2027 * -3.05x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
30/07 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
22/06 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
22/06 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
03/06 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
06/05 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02/04 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
04/03 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
27/02 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
26/02 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
19/12 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
07/12 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
14/11 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
12/11 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-1.03%
1 week+1.68%
Current month+3.42%
1 month-26.82%
3 months-38.53%
6 months-25.40%
Current year-23.16%
1 week 0.72
Extreme 0.716
0.78
1 month 0.72
Extreme 0.716
1.28
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
14.71
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/01/26 Free

General Counsel

3,50,000 0.6670%
20/01/26 Free

Chief Executive Officer

11,65,000 2.2203%
20/01/26 Free

Chief Technology Officer

4,20,000 0.8004%
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%+1.68%-55.58%-64.75% 5.1Cr
-3.25%+12.81%+52.96%+88.86% 6.49TCr
+0.69%+0.96%+29.39%+70.50% 5.41TCr
-1.65%-2.43%-18.61%-8.03% 2.32TCr
+30.85%+28.73%+17.43%+497.39% 2.15TCr
+1.87%+5.08%+29.88%-7.94% 2.13TCr
-0.79%+1.79%+36.31%-26.13% 1.79TCr
-3.37%+19.44%+211.98%+369.13% 1.7TCr
+3.29%+2.09%+17.32%+586.49% 1.5TCr
-7.20%-6.02%+39.49%+159.75% 1.43TCr
Average +1.93%+3.55%+36.06%+166.53% 2.49TCr
Weighted average by Cap. +1.46%+3.64%+42.89%+147.65%

Financials

2026 *2027 *
Net sales 75.57L 65.58L 61.41L 56.18L 1.06Cr 72Cr 1.07Cr 7.18Cr 2.82Cr 36Cr 2.84Cr 2.78Cr 119.72Cr 78.07L 67.75L 63.44L 58.03L 1.1Cr 74Cr 1.11Cr 7.42Cr 2.91Cr 37Cr 2.93Cr 2.87Cr 123.67Cr
Net income -12Cr -9.99Cr -9.35Cr -8.55Cr -16Cr -1.1TCr -16Cr -109.39Cr -43Cr -547.67Cr -43Cr -42Cr -1.82TCr -12Cr -11Cr -10Cr -9.28Cr -18Cr -1.19TCr -18Cr -118.66Cr -47Cr -594.06Cr -47Cr -46Cr -1.98TCr
Net Debt -9.89Cr -8.58Cr -8.03Cr -7.35Cr -14Cr -941.8Cr -14Cr -94Cr -37Cr -470.55Cr -37Cr -36Cr -1.57TCr -7.48Cr -6.49Cr -6.07Cr -5.56Cr -10Cr -712.12Cr -11Cr -71Cr -28Cr -355.8Cr -28Cr -27Cr -1.18TCr
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
07/26/07 $0.7684 -1.49% 1,14,310
05/26/05 $0.7800 +5.91% 2,98,715
04/26/04 $0.7365 +1.81% 7,96,346
03/26/03 $0.7234 -2.64% 4,41,443
31/26/31 $0.7430 -1.68% 2,53,902
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7800USD
Average target price
6.000USD
Spread / Average Target
+669.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock